tbuckley/cabot-search huggingface dataset:
Past use of hormone replacement therapy and risk of invasive breast cancer
Authors: W. Y. Chen, S. E. Hankinson, B. Rosner, G. A. Colditz
Journal: Journal of Clinical Oncology (2007)

10518 Background: Although current use of hormone replacement therapy (HRT) is associated with a greater risk of breast cancer than past use, the effects of longer term past use of HRT are not well quantified. Methods: We examined the relationship between past HRT use and invasive breast cancer risk within the Nurses’ Health Study, a prospective cohort of 121,700 registered nurses aged 30–55 in 1976 who update information on cancer risk factors and outcomes through biennial questionnaires. For this analysis, the follow-up period was 1980 through 2004 and only included person-time for postmenopausal women. Status of HRT use (never, past, or current), type of HRT (oral unopposed estrogen (E alone) or combination oral estrogen + progesterone (E+P)), and duration of HRT use were assessed every 2 years and defined prospectively. Proportional hazards models controlled for age, body mass index, parity, age at first birth, family history of breast cancer, benign breast disease, alcohol consumption, type of menopause, and ages at menarche and menopause. Results: During 1,388,368 person-years of follow-up among postmenopausal women, invasive breast cancer was diagnosed among 1,554 women who had never used HRT, 459 past users of E+P and 527 past users of E alone. Regardless of duration of use, past use of E alone was not associated with breast cancer risk. Although past use of E+P for less than 10 years was not associated with breast cancer risk (RR (95% CI) 1.01 (0.88–1.17) for &lt; 5 years and 0.95 (0.74–1.21) for 5–9.9 years), past use of E+P for greater than 10 years was associated with an increased risk of breast cancer (RR 1.53 (1.09–2.16) for 10–14.9 years and 1.48 (0.87–2.51) for 15 or more years). Results were similar regardless of time since last use, although power was limited for this subgroup analysis. Conclusions: Past use of E+P for greater than 10 years was associated with a persistent elevation in breast cancer risk. The relationship between duration of past use and breast cancer risk did not appear linear, but suggested a possible threshold effect. No significant financial relationships to disclose.
P1.09-05 ALK Testing in Chinese Advanced NSCLC Patients: A National-Wide Multicenter Prospective Real-World Data Study (The RATICAL Study)
Authors: J. Ying, L. Li, W. Li, Y. Li, Q. Xia, X. Teng, Y. Liu, G. Chen, X. Qiu, W. Wu, Y. Ji, Z. Wang, X. Yan, Y. Han, A. The Ratical Study Group
Journal: Journal of Thoracic Oncology (2019)
Association of a Multimodal Educational Intervention for Primary Care Physicians With Prescriptions of Buprenorphine for Opioid Use Disorders
Authors: Brinton Clark, Mari Kai, Ryan Dix, Jonathan White, Yelena Rozenfeld, Sheldon Levy, Kathleen Engstrom
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Opioid use disorder (OUD) is a public health crisis in the United States, but only 5% of US physicians have obtained a Drug Addiction Treatment Act (DATA) waiver to prescribe buprenorphine to treat OUD. Increasing the number of primary care physicians (PCPs) who have obtained the waiver and are able to treat patients with OUD is of utmost importance. <h3>Objective</h3> To determine whether a multimodal educational intervention of PCPs is associated with an increase in the number of buprenorphine waivers obtained and patients initiated into treatment in a primary care setting. <h3>Design, Setting, and Participants</h3> This quality improvement study was conducted in primary health care clinics within a large, integrated health care system. Patients included those who had received a diagnosis of OUD, and had Providence Health Plan Medicare or Medicaid insurance. Included PCPs were divided into 2 groups: those who obtained a DATA waiver after an education intervention (uptake PCPs) vs those who did not obtain a DATA waiver (nonuptake PCPs). The study took place between January 1, 2016, and December 31, 2017. Data analyses were conducted from December 2017 to August 2019. <h3>Exposures</h3> Multimodal educational intervention including video, in-person visits to clinical practitioner meetings by physician champions, and a primary care toolkit with training resources and clinic protocols. <h3>Main Outcomes and Measures</h3> The number of new uptake clinics where at least 1 PCP obtained a DATA waiver, the number of new PCPs with DATA waivers, the number of patients receiving a buprenorphine prescription, and the number of patients who received 12 or more weeks of treatment. <h3>Results</h3> Twenty-seven of 41 invited clinics implemented the intervention, and 620 PCPs were included. The number of PCPs with DATA waivers increased from 5 PCPs (0.8%) to 44 PCPs (7.1%), and the number of clinics with at least 1 buprenorphine prescriber increased from 3 clinics (7.3%) to 17 clinics (41.5%). In total, 213 patients underwent buprenorphine treatment, and 140 patients received 12 or more weeks of treatment. A total of 646 patients had Providence Health Plan Medicare or Medicaid insurance and were eligible for the study (mean [SD] age, 61.7 [16.5] years; 410 [63.5%] women). There was a statistically significant difference in treatment with buprenorphine between patients with uptake PCPs vs patients with nonuptake PCPs (23 patients [16.4%] vs 18 patients [3.5%]; odds ratio, 4.61 [95% CI, 2.32-10.51];<i>P</i> = .01) after the intervention. <h3>Conclusions and Relevance</h3> In this quality improvement study, an educational intervention was associated with an increase in the number of PCPs and clinics that could provide buprenorphine treatment for OUD and with an increase in the patients who were able to access care with medications for OUD.
Buried lumen-apposing metal stent after gastrojejunal bypass
Authors: Lorenzo Dioscoridi, Edoardo Forti, Francesco Pugliese, Marcello Cintolo, Giulia Bonato, Aurora Giannetti, Massimiliano Mutignani
Journal: Endoscopy (2019)

The possibilities of performing endoscopic gastroenteral bypass and entero-enteral bypass have been explored recently in patients with Roux-en-Y reconstruction after subtotal gastrectomy or biliary anastomosis; however, data are still scant and based on limited follow-up. The main adverse events described in the available literature are displacement or migration of the enteral stents, enteral perforations, and early bleeding [1] [2] [3]. We here describe the occurrence and our management of an intramural gastric partial migration of a lumen-apposing metal stent (LAMS), a rare adverse event of endoscopic gastroenteral bypass that has not yet been reported.
Adipocyte Hypoxia-Inducible Factor 2α Suppresses Atherosclerosis by Promoting Adipose Ceramide Catabolism
Authors: Xingzhong Zhang, Yangming Zhang, Pengcheng Wang, Song-Yang Zhang, Yongqiang Dong, Guangyi Zeng, Yu Yan, Lulu Sun, Qing Wu, Huiying Liu, Bo Liu, Wei Kong, Xian Wang, Changtao Jiang
Journal: Cell Metabolism (2019)

Obesity-induced adipose dysfunction is a major contributor to atherosclerosis. Cold exposure has been reported to affect atherosclerosis through regulation of adipose function, but the mechanism has not been well clarified. Here, adipocyte hypoxia-inducible factor 2α (HIF-2α) was upregulated after mild cold exposure at 16°C and mediated cold-induced thermogenesis. Adipocyte HIF-2α deficiency exacerbated Western-diet-induced atherosclerosis by increasing adipose ceramide levels, which blunted hepatocyte cholesterol elimination and thermogenesis. Mechanistically, Acer2, the gene encoding alkaline ceramidase 2, was identified as a novel target gene of HIF-2α, triggering ceramide catabolism. Adipose overexpression of ACER2 rescued adipocyte HIF-2α-deficiency-induced exacerbation of atherosclerosis. Furthermore, activation of adipose HIF-2α by the HIF prolyl hydroxylase inhibitor FG-4592 had protective effects on atherosclerosis, accompanied by a reduction in adipose and plasma ceramide and plasma cholesterol levels. This study highlights adipocyte HIF-2α as a putative drug target against atherosclerosis.
P1.18-21 Short and Mid-Term Outcomes of Multimodal Treatment for Locally-Advanced Non Small Cell Lung Cancer in Elderly Patients
Authors: S. Bongiolatti, F. Mazzoni, S. Borgianni, A. Gonfiotti, A. Salvicchi, L. Antonuzzo, L. Voltolini
Journal: Journal of Thoracic Oncology (2019)
Association of Apolipoprotein E ɛ4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults
Authors: Vijay K Ramanan, Anna M. Castillo, David S. Knopman, Jonathan Graff-Radford, Val J. Lowe, Ronald C. Petersen, Clifford R. Jack, Michelle M. Mielke, Prashanthi Vemuri
Journal: JAMA Network Open (2019)

While amyloidosis is an early event in the Alzheimer disease (AD) biomarker cascade, a complex interplay among the apolipoprotein E (APOE) ɛ4 allele, educational levels, and sex may be associated with an individual's resilience to dementia.
P2.15-12 Epidemiology of Thymic Epithelial Tumors: 22-Year Experience from a Single-Institution
Authors: P. Rioja, S. Lozano, R. Ruiz, M. Galvez Nino, N. Valdivieso, M. Olivera, O. Cabero, M. Guillen, A. De La Guerra, E. Amorin, C. Barrionuevo, L. Mas
Journal: Journal of Thoracic Oncology (2019)
P1.04-05 PD-L1 Expression (SP263) in Lung Cancer and Paired Brain Metastases – A Single Center Study in 211 Patients
Authors: A. Kündig, C. Fung, A. Scherz, A. Ochsenbein, E. Herrmann, E. Ermis, R. Schmid, E. Hewer, S. Berezowska
Journal: Journal of Thoracic Oncology (2019)
MA02.10 Different Prognostic Impact of Lymphovascular Invasion Between Lobectomy and Sublobar Resection in Stage IA Non-Small Cell Lung Cancer: A Propensity Score–Matched Analysis
Authors: J.K. Yun, G.D. Lee, Y. Chong, Y.H. Jeong, S. Choi, H.R. Kim, Y. Kim, D.K. Kim, S. Park
Journal: Journal of Thoracic Oncology (2019)
P2.14-42 Emergence of CCDC6-RET Fusion with Maintained EGFR T790M Mutation After Resistance to Osimertinib in NSCLC: A Case Report
Authors: Y. Guo, R. Guo, H. Cheng, H. Wang, F. Lou, S. Cao, W. Guo, X. Song
Journal: Journal of Thoracic Oncology (2019)
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Authors: Andrew A. Davis, Vaibhav G. Patel
Journal: Journal for ImmunoTherapy of Cancer (2019)

The development of immune checkpoint inhibitors has changed the treatment paradigm for advanced cancers across many tumor types. Despite encouraging and sometimes durable responses in a subset of patients, most patients do not respond. Tumors have adopted the PD-1/PD-L1 axis for immune escape to facilitate tumor growth, which can be leveraged as a potential target for immune checkpoint inhibitors. On this basis, PD-L1 protein expression on tumor or immune cells emerged as the first potential predictive biomarker for sensitivity to immune checkpoint blockade. The goal of our study was to evaluate PD-L1 as a predictive biomarker based on all US Food and Drug Administration (FDA) drug approvals of immune checkpoint inhibitors. We evaluated the primary studies associated with 45 FDA drug approvals from 2011 until April 2019. In total, there were approvals across 15 tumor types. Across all approvals, PD-L1 was predictive in only 28.9% of cases, and was either not predictive (53.3%) or not tested (17.8%) in the remaining cases. There were 9 FDA approvals linked to a specific PD-L1 threshold and companion diagnostic: bladder cancer (N = 3), non-small cell lung cancer (N = 3), triple-negative breast cancer (N = 1), cervical cancer (N = 1), and gastric/gastroesophageal junction cancer (N = 1) with 8 of 9 (88.9%) with immune checkpoint inhibitor monotherapy. The PD-L1 thresholds were variable both within and across tumor types using several different assays, including approvals at the following PD-L1 thresholds: 1, 5, and 50%. PD-L1 expression was also measured in a variable fashion either on tumor cells, tumor-infiltrating immune cells, or both. In conclusion, our findings indicate that PD-L1 expression as a predictive biomarker has limitations and that the decision to pursue testing must be carefully implemented for clinical decision-making.
Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials
Authors: Ioannis Parodis, Sharzad Emamikia, Alvaro Gomez, Cidem Gentline, Elizabeth V Arkema, Katerina Chatzidionysiou, Ronald F van Vollenhoven
Journal: The Lancet Rheumatology (2019)
Investigating the developmental impacts of schizophrenia risk alleles and childhood peer victimization on early-onset mental health trajectories
Authors: Lucy Riglin, Gemma Hammerton, Jon Heron, Stephen Collishaw, Louise Arseneault, Ajay K Thapar, Barbara Maughan, Michael C. O'Donovan, Anita Thapar
Journal: American Journal of Psychiatry (2018)
CCG 1953: Acute Lymphoblastic Leukemia in Infants: Analysis of Prognostic Factors: A Report from the Children’s Oncology Group.
Authors: Joanne M. Hilden, Patricia A. Dinndorf, Sharon O. Meerbaum, Harland Sather, Doojduen Villaluna, Nyla A. Heerema, Ron McGlennen, Franklin O. Smith, William G. Woods, Zoann Dryer, Gregory H. Reaman
Journal: Blood (2005)
Strengthening the Evidence for Cardiac Rehabilitation Benefits
Authors: Randal J. Thomas, LaPrincess C. Brewer
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
A Gene Expression–based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients
Authors: Stefano Luminari, Benedetta Donati, Massimiliano Casali, Riccardo Valli, Raffaella Santi, Benedetta Puccini, Sofya Kovalchuk, Alessia Ruffini, Angelo Fama, Valentina Berti, Valentina Fragliasso, Magda Zanelli, Federica Vergoni, Annibale Versari, Luigi Rigacci, Francesco Merli, Alessia Ciarrocchi
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Early response to ABVD, assessed with interim FDG-PET (iPET), is prognostic for classical Hodgkin lymphoma (cHL) and supports the use of response adapted therapy. The aim of this study was to identify a gene-expression profile on diagnostic biopsy to predict iPET positivity (iPET+). Experimental Design: Consecutive untreated patients with stage I–IV cHL who underwent iPET after two cycles of ABVD were identified. Expression of 770 immune-related genes was analyzed by digital expression profiling (NanoString Technology). iPET was centrally reviewed according to the five-point Deauville scale (DS 1-5). An iPET+ predictive model was derived by multivariate regression analysis and assessed in a validation set identified using the same inclusion criteria. Results: A training set of 121 and a validation set of 117 patients were identified, with 23 iPET+ cases in each group. Sixty-three (52.1%), 19 (15.7%), and 39 (32.2%) patients had stage I–II, III, and IV, respectively. Diagnostic biopsy of iPET+ cHLs showed transcriptional profile distinct from iPET−. Thirteen genes were stringently associated with iPET+. This signature comprises two functionally stromal-related nodes. Lymphocytes/monocytes ratio (LMR) was also associated to iPET+. In the training cohort a 5-gene/LMR integrated score predicted iPET+ [AUC, 0.88; 95% confidence interval (CI), 0.80–0.96]. The score achieved a 100% sensitivity to identify DS5 cases. Model performance was confirmed in the validation set (AUC, 0.68; 95% CI, 0.52–0.84). Finally, iPET score was higher in patients with event versus those without. Conclusions: In cHL, iPET is associated with a genetic signature and can be predicted by applying an integrated gene-based model on the diagnostic biopsy.
P1.01-04 A Phase II Trial of Weekly Nab-Paclitaxel in the Salvage Setting for Advanced Non-Small Cell Lung Cancer: Results of NICE Salvage Study 
Authors: Y. Kogure, T. Niwa, H. Yoshioka, H. Saka, A. Hata, N. Katakami, Y. Ozawa, N. Matsuo, T. Hoshino, K. Wakuda, H. Kenmotsu, T. Takahashi, K. Nosaki, M. Takenoyama, M. Tajima, K. Takahashi, M. Ando, N. Yamamoto
Journal: Journal of Thoracic Oncology (2019)
EP1.01-68 Impact of EGFR Genotype on the Efficacy of Osimertinib in Patients with Non-Small Cell Lung Cancer: A Prospective Observational Study
Authors: S. Igawa, T. Ono, T. Ozawa, H. Sone, S. Kusuhara, S. Harada, M. Ishihara, M. Kasajima, Y. Hiyoshi, T. Fukui, M. Kubota, J. Sasaki, H. Mitsufuji, K. Naoki
Journal: Journal of Thoracic Oncology (2019)
Gut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of <i>Trichocladium griseum</i> and <i>Candida</i> species
Authors: Malte Christoph Rühlemann, Miriam Emmy Leni Solovjeva, Roman Zenouzi, Timur Liwinski, Martin Kummen, Wolfgang Lieb, Johannes Roksund Hov, Christoph Schramm, Andre Franke, Corinna Bang
Journal: Gut (2019)

We read with interest the recent Gut article by Lemoinne et al describing a dysbiosis of the fungal gut community in faeces of patients suffering from primary sclerosing cholangitis (PSC).1 Though several reports, including our own previous data, support a functional and potentially pathogenic link between the intestinal bacteriota and liver inflammation in PSC,2 3 the aetiology of the disease remains largely unknown.

We here report on the fungal mycobiome results of our cohort from Northern Germany approved by the local ethics committees (A148/14 and MC-111/15) comprising stool samples of 66 healthy control (HC) subjects, 65 patients with well-characterised PSC (including a subgroup with concomitant colitis (PSC-IBD), n=32) and 38 subjects with UC.3 PCR and sequencing of the fungus-specific internal transcribed spacer 2 genomic region was performed as previously described4 using the primer pair 5.8S-Fun and ITS4-Fun on an Illumina MiSeq machine. Sequencing data were subjected to quality control by using the open source package DADA2 (V.1.10)5 in R (V.3.5.1; https://github.com/mruehlemann/ikmb\_amplicon\_processing). Amplicon sequence variants were taxonomically annotated using the UNITE ITS database (V.7.2).6 

In disagreement with the findings in the French cohort,1 overall fungal alpha diversity in the German cohort was neither altered in PSC nor …
RET-Rearranged Lung Adenocarcinoma with Paraneoplastic Meige Syndrome
Authors: Baptiste Abbar, Carole Henry, Nathalie Theou-Anton, Solenn Brosseau, Marina Nguenang, Johan Pluvy, Sandra Assoun, Gérard Zalcman, Valérie Gounant
Journal: Journal of Thoracic Oncology (2019)
P2.06-11 MEDUSA: Phylogenetic Analysis of Mesothelioma Tumours by Multiregional Sampling, Whole Exome Sequencing, and Copy Number Analysis
Authors: E. Hollox, L. Brannan, A. Nakas, M. Jama, A. Sharkey, A. Dawson, J. Le Quesne, F. Dudbridge, D. Fennell
Journal: Journal of Thoracic Oncology (2019)
EP1.16-08 Behobiamediopulmon: Putting Face and Running Shoes on Patients with Lung Cancer
Authors: J. Zabaleta, B. Gaspar, I. Etxeberria, M. Cruzado, B. Aguinagalde, I. López, A. Fernandez-Monge, J. Izquierdo, F. Hernando-Trancho
Journal: Journal of Thoracic Oncology (2019)
PL02.02 Lung Cancer Screenee Selection by USPSTF Versus PLCOm2012 Criteria – Interim ILST Findings
Authors: S. Lam, R. Myers, M. Ruparel, S. Atkar-Khattra, E. Stone, R. Manser, A. Mcwilliams, P. Fogarty, D. Lam, J. Yee, J. Mayo, C. Berg, S. Janes, K. Fong, M. Tammemagi
Journal: Journal of Thoracic Oncology (2019)
P2.14-20 ATORG-003: Dacomitinib With or Without Dose Titration as First-Line Therapy for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)
Authors: A. Tan, T. Mok, D. Kim, J.C. Yang, C. Lee, R. Soo, T. Reungwetwattana, D. Tan, H. Loong
Journal: Journal of Thoracic Oncology (2019)
Improving Molecular Oncology by Making Results Available to Patients
Authors: Geoffrey R. Oxnard, Howard (Jack) West, Jennifer C. King
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
P1.01-91 Clinical Outcomes of Various Resistance Mechanisms of Osimertinib in Chinese Advanced Non-Small Cell Lung Cancer Patients
Authors: P. Xing, Y. Mu, S. Wang, D. Ma, J. Lin, H. Liu, H. Han-Zhang, A. Lizaso, J. Xiang, X. Mao, X. Hao, J. Li
Journal: Journal of Thoracic Oncology (2019)
EP1.01-56 Co-Presentation of Adenocarcinoma and Squamous Cell Lung Carcinoma Harbouring ALK Rearrangement in Different Sites
Authors: V. Longo, A. Catino, D. Galetta, G. Del Bene, R. Lacalamita, M. Montrone, F. Pesola, D. Petriella, P. Pizzutilo, S. Tommasi
Journal: Journal of Thoracic Oncology (2019)
EP1.03-15 Comparison of Plasma Expression of Drosha and Dicer mRNAs in Early and Advanced Stages of NSCLC Patients
Authors: A. Grenda, M. Szczyrek, B. Kuźnar-Kamińska, P. Krawczyk, G. Balicka, M. Jakimiec, H. Batura-Gabryel, M. Sawicki, J. Milanowski
Journal: Journal of Thoracic Oncology (2019)
P2.01-94 Advanced Age and High Modiﬁed Glasgow Prognostic Score Are Associated with Increased Complications After Pneumonectomy
Authors: M. Zaatar, T. Stork, L. Fangmann, A. Martens, S. Collaud, K. Mardanzai, T. Plönes, D. Valdivia, M. Schuler, M. Stuschke, K. Darwiche, B. Hegedus, C. Aigner
Journal: Journal of Thoracic Oncology (2019)
P2.14-30 Predictive Value of ctDNA in Patients with EGFR Positive NSCLC Receiving 3rd Generation TKI
Authors: F. Moiseenko, M. Stepanova, A. Zhabina, A. Myslik, V. Klimenko, D. Krylova, N. Rysev, N. Volkov, V. Moiseenko
Journal: Journal of Thoracic Oncology (2019)
P2.08-05 The Role of Surgical Treatment for Patients with NSCLC Demonstrating Limited Pleural Dissemination
Authors: H. Matsuguma, I. Wakamatsu, R. Nakahara, T. Sugiyama, Y. Nakamura, T. Kasai, Y. Kamiyama, N. Hoshi
Journal: Journal of Thoracic Oncology (2019)
P1.16-29 Profiling Immune-Related Adverse Events (irAEs) in Patients with Anti-PD-1 for Advanced Non-Small Cell Lung Cancer
Authors: Y. Toi, S. Sugawara, M. Aso, K. Tsurumi, K. Ono, J. Sugisaka, H. Shimizu, H. Ono, Y. Domeki, T. Aiba, S. Kawana, R. Saito, K. Terayama, Y. Kawashima, A. Nakamura, S. Yamanda, Y. Kimura, Y. Honda
Journal: Journal of Thoracic Oncology (2019)